Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid Lactation Study
NCT06021951Phase 4Completed
- Sponsor
- Esperion Therapeutics
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bempedoic acid in hypercholesterolemia (2 arms), sponsored by Esperion Therapeutics. Primary endpoints: Daily Infant Dose and Relative Infant Dose. Started Aug 2023; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06021951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021951.